Redmile Group’s Kalaris Therapeutics KLRS Stock Holding History

Redmile Group’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-82,955	Closed	-$700K	–	39
2025 Q4	$700K	Hold	82,955	–	–	0.05%	34
2025 Q3	$479K	Hold	82,955	–	–	0.05%	39
2025 Q2	$221K	Hold	82,955	–	–	0.02%	48
2025 Q1	$666K	Hold	82,955	–	–	0.06%	55
2024 Q4	$801K	Hold	82,955	–	–	0.06%	59
2024 Q3	$1.54M	Hold	82,955	–	–	0.09%	60
2024 Q2	$1.38M	Hold	82,955	–	–	0.08%	58
2024 Q1	$1.44M	Hold	82,955	–	–	0.05%	73
2023 Q4	$1.3M	Hold	82,955	–	–	0.05%	63
2023 Q3	$4.1M	Hold	82,955	–	–	0.2%	54
2023 Q2	$6.49M	Hold	82,955	–	–	0.25%	55
2023 Q1	$7.52M	Hold	82,955	–	–	0.33%	56
2022 Q4	$9.79M	Hold	82,955	–	–	0.4%	48
2022 Q3	$15.1M	Buy	82,955 +47,156	+132%	+$7.35M	0.58%	46
2022 Q2	$3.21M	Hold	35,799	–	–	0.12%	63
2022 Q1	$5.56M	Hold	35,799	–	–	0.17%	60
2021 Q4	$10.7M	Sell	35,799 -588	-2%	-$273K	0.24%	57
2021 Q3	$21M	Sell	36,387 -32,487	-47%	-$15M	0.37%	54
2021 Q2	$31.3M	Sell	68,874 -15,630	-18%	-$8.07M	0.46%	54
2021 Q1	$45.5M	Sell	84,504 -16,609	-16%	-$14M	0.64%	49
2020 Q4	$89.4M	Sell	101,113 -339	-0.3%	-$261K	1.08%	30
2020 Q3	$64.2M	Buy	+101,452	New	+$69.3M	1.18%	30

Other funds holding KLRS

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Redmile Group's KLRS Position: Q1 2026 in Review

Redmile Group sold out of Kalaris Therapeutics (KLRS) in Q1 2026, closing a stake of 82,955 shares — an estimated $700K sold.

Redmile Group first reported a position in KLRS in Q3 2020 and held it in 22 quarters. The position peaked at $89.4M in Q4 2020. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

Redmile Group reported no remaining Kalaris Therapeutics position as of Q1 2026 after selling out during the quarter.
Redmile Group sold 82,955 Kalaris Therapeutics shares in Q1 2026, an estimated $700K.
Redmile Group first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 22 quarters.
Redmile Group's Kalaris Therapeutics position peaked at $89.4M in Q4 2020.
58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.